Analysis of the European HIV Drugs Market

This research service provides an in-depth analysis of the HIV drugs market across Europe. It analyses the revenue potential, market dynamics, trends, and the competitive structure. The revenue values of the European HIV drugs market have been derived from market sales and pipeline investment made under drug classes like nucleoside reverse transcriptase inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors and integrase inhibitors. The market analysed in this research service has been approached from a manufacturer's point of view. Apart from segmentation by drug classes, the market has also been broken down based on major Western European countries.
Published: 23 Jan 2013

  1. Executive Summary
  2. Market Overview
  3. Total HIV Drugs Market
    • External Challenges: Drivers and Restraints
    • Forecast and Trends
    • Market Share and Competitive Analysis
  4. Segment Breakdown
    • Nucleoside Reverse Transcriptase Inhibitor
    • Protease Inhibitors
    • Non-Nucleoside Reverse Transcriptase Inhibitor
    • Integrase Inhibitors
    • Other Therapeutics
  5. Segment Breakdown by Geography
    • The United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • The Benelux Region
    • The Scandinavian Region
  6. The Last Word
  7. Appendix

Features of this Research

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..